Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

360 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-06-30

Study Completion Date

2005-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the efficacy of paclitaxel- and sirolimus-eluting stents to prevent re-blockage of small coronary arteries

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)

NCT00133237

Coronary Disease

COMPLETED PHASE4

Coroflex ISAR 2000 Registry

NCT02629575

Coronary Artery Disease (CAD)

COMPLETED

Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)

NCT00140530

Coronary Disease

COMPLETED PHASE4

Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization

NCT00297661

Coronary Heart Disease

COMPLETED PHASE4

Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents

NCT00598715

Coronary Artery Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although use of bare metal stents has reduced restenosis in coronary vessels with a diameter ≥3 mm when compared to plain balloon angioplasty, most of the dedicated randomized studies have failed to show a beneficial effect of stent over balloon angioplasty in vessels with a small reference diameter. In spite of refinements in stent design and periprocedural therapy, the risk of restenosis after bare metal stenting in this setting remains elevated. Nowadays, percutaneous coronary interventions in small vessels account for 35-67% of interventional procedures performed in patients with coronary artery disease and, when bare metal stents are used, restenosis will be detected in more than 35% of the treated patients and a repeat revascularization procedure will be needed in more than 20% them. Several randomized trials have shown that stents eluting antiproliferative drugs, with sirolimus- and paclitaxel-eluting stents the only devices approved for commercial use so far, are highly effective in reducing restenosis when compared with bare metal stents. Subgroup analysis from these trials have shown that the efficacy of either sirolimus stent or paclitaxel stent extends also to those patients who undergo coronary stenting in small sized vessels. In addition, three randomized studies of sirolimus-eluting stents and bare metal stents used in coronary arteries smaller than 3 mm have reported 82-96% reduction in the relative risk of restenosis with the sirolimus stents thus, providing convincing evidence on the role of drug-eluting stents as an effective treatment strategy for coronary arteries with a small reference diameter.

At present, there is no direct evidence on the relative efficacy in the prevention of restenosis of sirolimus stent and paclitaxel stent after implantation in small coronary vessels. Selecting the most effective device for this particularly high-risk category that accounts for a large proportion of percutaneous coronary interventions, may have important clinical and economic implications. Comparisons of data from subgroup analysis of different trials have suggested that there might be differences in the efficacy to prevent restenosis between sirolimus and paclitaxel stents. However, indirect comparisons are subject to many limitations and consequently, conclusions based on their results may be erroneous. Therefore, reliable guidance on the selection of the most effective drug-eluting stent for treatment of lesions in coronary vessels with a small reference diameter could be provided only from a head-to-head comparison between these devices.

Comparison:

Sirolimus-eluting stent and paclitaxel-eluting stent in patients undergoing stenting in small coronary vessels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

randomized patients get sirolimus stent

Group Type EXPERIMENTAL

Sirolimus-eluting stent (Cypher)

Intervention Type DEVICE

patients have been implanted a Cypher stent

2

randomized patients get paclitaxel stent

Group Type EXPERIMENTAL

Paclitaxel-eluting stent (Taxus)

Intervention Type DEVICE

patients have been implanted a Taxus stent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sirolimus-eluting stent (Cypher)

patients have been implanted a Cypher stent

Intervention Type DEVICE

Paclitaxel-eluting stent (Taxus)

patients have been implanted a Taxus stent

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cypher Taxus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stable or unstable angina pectoris and/or a positive stress test
* "de novo" lesion in small coronary arteries (vessel size \<2.8 mm by visual estimation)
* Written informed consent

Exclusion Criteria

* Diabetes mellitus
* Myocardial infarction within 48 h. before enrollment
* Target lesion located in the left main trunk or bypass graft
* Contraindication or known allergy to aspirin, thienopyridines, rapamycin, paclitaxel or stainless steel

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No